United States· US:0019-1323_1884aaeb-c174-4df7-a710-82d2b1869ad2
Optiray
A ioversol product containing ioversol, registered in United States by Liebel-Flarsheim Company LLC. The same ATC class is registered in 14 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Ioversol is registered in 14 of 19 countries.
Countries holding a registration under ATC V08AB07 (ioversol), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 7 of them publish a price we can compare per daily dose
Ioversol · ATC V08AB07
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Ireland
- Japan
- Netherlands
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- IOVERSOL
- Manufacturer
- Liebel-Flarsheim Company LLC
- Country
- United States (US)
- ATC code
- V08AB07
- ATC class
- Ioversol
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 44
- ndc110019-1323-06
- ndc11001913230020 SYRINGE, PLASTIC in 1 CARTON (0019-1323-00) / 100 mL in 1 SYRINGE, PLASTIC
- ndc11001913230225 VIAL, GLASS in 1 CARTON (0019-1323-02) / 20 mL in 1 VIAL, GLASS
- ndc11001913230425 VIAL, GLASS in 1 CARTON (0019-1323-04) / 30 mL in 1 VIAL, GLASS
- ndc11001913230625 BOTTLE, GLASS in 1 CARTON (0019-1323-06) / 50 mL in 1 BOTTLE, GLASS
- ndc11001913231112 BOTTLE, GLASS in 1 CARTON (0019-1323-11) / 100 mL in 1 BOTTLE, GLASS
- ndc11001913231612 BOTTLE, GLASS in 1 CARTON (0019-1323-16) / 150 mL in 1 BOTTLE, GLASS
- ndc11001913232112 BOTTLE, GLASS in 1 CARTON (0019-1323-21) / 200 mL in 1 BOTTLE, GLASS
- ndc11001913232720 SYRINGE, PLASTIC in 1 CARTON (0019-1323-27) / 125 mL in 1 SYRINGE, PLASTIC
- ndc11001913235220 SYRINGE, PLASTIC in 1 CARTON (0019-1323-52) / 50 mL in 1 SYRINGE, PLASTIC
- ndc11001913235520 SYRINGE, PLASTIC in 1 CARTON (0019-1323-55) / 50 mL in 1 SYRINGE, PLASTIC
- ndc11001913237020 SYRINGE, PLASTIC in 1 CARTON (0019-1323-70) / 30 mL in 1 SYRINGE, PLASTIC
- ndc11001913237320 SYRINGE, PLASTIC in 1 CARTON (0019-1323-73) / 30 mL in 1 SYRINGE, PLASTIC
- ndc11001913237520 SYRINGE, PLASTIC in 1 CARTON (0019-1323-75) / 50 mL in 1 SYRINGE, PLASTIC
- ndc11001913237720 SYRINGE, PLASTIC in 1 CARTON (0019-1323-77) / 50 mL in 1 SYRINGE, PLASTIC
- ndc11001913237820 SYRINGE, PLASTIC in 1 CARTON (0019-1323-78) / 50 mL in 1 SYRINGE, PLASTIC
- ndc11001913238120 SYRINGE, PLASTIC in 1 CARTON (0019-1323-81) / 125 mL in 1 SYRINGE, PLASTIC
- ndc11001913238320 SYRINGE, PLASTIC in 1 CARTON (0019-1323-83) / 100 mL in 1 SYRINGE, PLASTIC
- ndc11001913238520 SYRINGE, PLASTIC in 1 CARTON (0019-1323-85) / 75 mL in 1 SYRINGE, PLASTIC
- ndc11001913238720 SYRINGE, PLASTIC in 1 CARTON (0019-1323-87) / 125 mL in 1 SYRINGE, PLASTIC
- ndc11001913239020 SYRINGE, PLASTIC in 1 CARTON (0019-1323-90) / 100 mL in 1 SYRINGE, PLASTIC
- ndc11001913239120 SYRINGE, PLASTIC in 1 CARTON (0019-1323-91) / 75 mL in 1 SYRINGE, PLASTIC
- ndc11001913239520 SYRINGE, PLASTIC in 1 CARTON (0019-1323-95) / 75 mL in 1 SYRINGE, PLASTIC
- ndc110019-1323-00
- ndc110019-1323-02
- ndc110019-1323-04
- ndc110019-1323-11
- ndc110019-1323-16
- ndc110019-1323-21
- ndc110019-1323-27
- ndc110019-1323-52
- ndc110019-1323-55
- ndc110019-1323-70
- ndc110019-1323-73
- ndc110019-1323-75
- ndc110019-1323-77
- ndc110019-1323-78
- ndc110019-1323-81
- ndc110019-1323-83
- ndc110019-1323-85
- ndc110019-1323-87
- ndc110019-1323-90
- ndc110019-1323-91
- ndc110019-1323-95
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
188 interactions on record for ioversol.
Graded by severity as the source publishes them — 94 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Ioversol · interactions on record
188 records
- 94 severe
- 55 moderate
- 39 info
Most severe, free to view
- NeomycinA07AA01severe
- StreptomycinA07AA04severe
- Polymyxin BA07AA05severe
- Amphotericin BA07AA07severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Ioversol in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumOptiject 240 mg I/mlGuerbet
- CzechiaOPTIRAYGuerbet, Roissy CdG Cedex
- United KingdomOptiray 160 solution for infusion 50ml bottlesCovidien (UK) Commercial Ltd
- Japanイオベルソールゲルベ・ジャパン
- FinlandOptirayGuerbet
- SpainOPTIRAY 240 mg/ml SOLUCION INYECTABLEGuerbet
- SwedenOptiray (flerdos) 300 mg I/ml Injektions-/infusionsvätska, lösningGuerbet
- IrelandOptiray 300 mg I/ml PFS solution for injectionGuerbet
Authorised across Europe · EMA
The same active substance is authorised in 22 EEA countries. Names it is sold under:
- Austria · Optiray
- Belgium · Optiject, Optiray
- Czechia · Optiray
- Germany · Optiray
- Denmark · Optiray
- Spain · Optiray, Optiray Ultraject
- Finland · Optiray
- France · Optiject, Optiray
- United Kingdom (Northern Ireland) · Optiray
- Greece · Optiray
- Croatia · Optiray
- Hungary · Optiray
- Ireland · Optiray
- Italy · Optiray
- Luxembourg · Optiject, Optiray
- Netherlands · Optiray
- Norway · Optiray
- Poland · Optiray
- Portugal · Optiray
- Romania · Optiray
- Sweden · Optiray
- Slovakia · Optiray
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/48ece6f5-69f2-46a3-af81-1dff15e01984 GET /v1/drugs/48ece6f5-69f2-46a3-af81-1dff15e01984?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "INTRA-ARTERIAL; INTRAVENOUS",
"source": "ndc",
"strength": "678",
"substance": "IOVERSOL",
"productndc": "0019-1323",
"dosage_form": "INJECTION",
"dea_schedule": null,
"strength_unit": "mg/mL",
"application_number": "NDA019710",
"marketing_category": "NDA"
}See everything about ioversol.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.